ArticleOphthalmology and therapy2020
Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach.
Article in Ophthalmology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.Acta ophthalmologica · 2026Trial
- Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Trial
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Outcomes of Treatment for Central Serous Chorioretinopathy With Half-Fluence, Half-Dose Photodynamic Therapy.Journal of vitreoretinal diseases · 2026Article
- Prevalence of central serous chorioretinopathy in Denmark.Acta ophthalmologica · 2025Article
- Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.Ophthalmology and therapy · 2025Article
- Verteporfin attenuates NLRP3 inflammasome activation to alleviate gout arthritis flares.Journal of inflammation (London, England) · 2025Article
- Ocular Drug Delivery: Emerging Approaches and Advances.Pharmaceutics · 2025Review
- Oscillatory photodynamic therapy in central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Predictive risk scores for visual prognosis after photodynamic therapy for central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Perspectives and Update on the Global Shortage of Verteporfin (VisudyneOphthalmology and therapy · 2024Article
- Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy.International journal of retina and vitreous · 2024Article
- Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China.Annals of medicine · 2023Article
- Scientific Literature Database Coverage of Randomized Clinical Trials for Central Serous Chorioretinopathy.Journal of personalized medicine · 2023Article
- Risk of Central Serous Chorioretinopathy in Male Androgen Abusers.Ophthalmology and therapy · 2023Article
- Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Masquerade Case: Choroidal Hemangioma Misdiagnosed As Central Serous Retinopathy.International medical case reports journal · 2023Article
- Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.Acta ophthalmologica · 2022Article
- Novel Short PEG Chain-Substituted Porphyrins: Synthesis, Photochemistry, and In Vitro Photodynamic Activity against Cancer Cells.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) using verteporfin (Visudyne®; Bausch + Lomb) is a treatment that is widely used to elicit cell and tissue death. In ophthalmology, PDT targets choroidal vascular abnormalities and induces selective occlusion of vessels. PDT was originally used in combination with full-dose verteporfin to treat neovascular age-related macular degeneration. Since the introduction of treatment with vascular endothelial growth factor receptor inhibitors, the clinical targets of PDT have shifted to other chorioretinal conditions, such as central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal hemangioma. In recent years, clinical studies have facilitated the optimization of treatment outcomes through changes in protocols, including the introduction of reduced treatment settings, such as PDT with half-dose verteporfin and half-fluence PDT. Here, we review PDT and its use for chorioretinal diseases from a practical perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.